Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants

  1. Adam R Blanden
  2. Xin Yu
  3. Alan J Blayney
  4. Christopher Demas
  5. Jeung-Hoi Ha
  6. Yue Liu
  7. Tracy Withers
  8. Darren R Carpizo  Is a corresponding author
  9. Stewart N Loh  Is a corresponding author
  1. SUNY Upstate Medical University, United States
  2. Rutgers Cancer Institute of New Jersey, United States
  3. University of Rochester Medical Center, United States

Abstract

Missense mutations in the p53 DNA binding domain (DBD) contribute to half of new cancer cases annually. Here we present a thermodynamic model that quantifies and links the major pathways by which mutations inactivate p53. We find that DBD possesses two unusual properties-one of the highest zinc affinities of any eukaryotic protein and extreme instability in the absence of zinc-which are predicted to poise p53 on the cusp of folding/unfolding in the cell, with a major determinant being available zinc concentration. We analyze the 20 most common tumorigenic p53 mutations and find that 80% impair zinc affinity, thermodynamic stability, or both. Biophysical, cell-based, and murine xenograft experiments demonstrate that a synthetic zinc metallochaperone rescues not only mutations that decrease zinc affinity, but also mutations that destabilize DBD without impairing zinc binding. The results suggest that zinc metallochaperones have the capability to treat 120,500 patients annually in the U.S.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Adam R Blanden

    Neurology, SUNY Upstate Medical University, Syracuse, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Xin Yu

    Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Alan J Blayney

    Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0741-1550
  4. Christopher Demas

    Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jeung-Hoi Ha

    Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Yue Liu

    Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Tracy Withers

    Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Darren R Carpizo

    Surgery, University of Rochester Medical Center, Rochester, United States
    For correspondence
    darren_carpizo@urmc.rochester.edu
    Competing interests
    The authors declare that no competing interests exist.
  9. Stewart N Loh

    Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, United States
    For correspondence
    lohs@upstate.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4387-9644

Funding

National Institutes of Health (F30 GM113299)

  • Adam R Blanden
  • Stewart N Loh

National Institutes of Health (R01 CA200800)

  • Darren R Carpizo

National Institutes of Health (K08 CA172676)

  • Darren R Carpizo

Breast Cancer Research Foundation

  • Darren R Carpizo

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Sarel Jacob Fleishman, Weizmann Institute of Science, Israel

Ethics

Animal experimentation: Mice were housed and treated according to guidelines established by the Institutional Animal Care and Use Committee of Rutgers University, who also approved all mouse experiments. (animal protocol PROTO99900044, approval date 10/16/2019 - 10/15/2022).

Version history

  1. Received: July 27, 2020
  2. Accepted: November 19, 2020
  3. Accepted Manuscript published: December 2, 2020 (version 1)
  4. Version of Record published: December 10, 2020 (version 2)

Copyright

© 2020, Blanden et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,867
    views
  • 610
    downloads
  • 46
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Adam R Blanden
  2. Xin Yu
  3. Alan J Blayney
  4. Christopher Demas
  5. Jeung-Hoi Ha
  6. Yue Liu
  7. Tracy Withers
  8. Darren R Carpizo
  9. Stewart N Loh
(2020)
Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants
eLife 9:e61487.
https://doi.org/10.7554/eLife.61487

Share this article

https://doi.org/10.7554/eLife.61487

Further reading

    1. Cancer Biology
    Pirunthan Perampalam, James I MacDonald ... Frederick A Dick
    Research Article

    Dormancy in cancer is a clinical state in which residual disease remains undetectable for a prolonged duration. At a cellular level, rare cancer cells cease proliferation and survive chemotherapy and disseminate disease. We created a suspension culture model of high-grade serous ovarian cancer (HGSOC) dormancy and devised a novel CRISPR screening approach to identify survival genes in this context. In combination with RNA-seq, we discovered the Netrin signaling pathway as critical to dormant HGSOC cell survival. We demonstrate that Netrin-1, –3, and its receptors are essential for low level ERK activation to promote survival, and that Netrin activation of ERK is unable to induce proliferation. Deletion of all UNC5 family receptors blocks Netrin signaling in HGSOC cells and compromises viability during the dormancy step of dissemination in xenograft assays. Furthermore, we demonstrate that Netrin-1 and –3 overexpression in HGSOC correlates with poor outcome. Specifically, our experiments reveal that Netrin overexpression elevates cell survival in dormant culture conditions and contributes to greater spread of disease in a xenograft model of abdominal dissemination. This study highlights Netrin signaling as a key mediator HGSOC cancer cell dormancy and metastasis.

    1. Cancer Biology
    2. Cell Biology
    Camille Dantzer, Justine Vaché ... Violaine Moreau
    Research Article

    Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of ß-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which oncogenic ß-catenin affects immune surveillance remain unclear. Herein, we highlighted the involvement of ß-catenin in the regulation of the exosomal pathway and, by extension, in immune/cancer cell communication in hepatocellular carcinoma (HCC). We showed that mutated ß-catenin represses expression of SDC4 and RAB27A, two main actors in exosome biogenesis, in both liver cancer cell lines and HCC patient samples. Using nanoparticle tracking analysis and live-cell imaging, we further demonstrated that activated ß-catenin represses exosome release. Then, we demonstrated in 3D spheroid models that activation of β-catenin promotes a decrease in immune cell infiltration through a defect in exosome secretion. Taken together, our results provide the first evidence that oncogenic ß-catenin plays a key role in exosome biogenesis. Our study gives new insight into the impact of ß-catenin mutations on tumor microenvironment remodeling, which could lead to the development of new strategies to enhance immunotherapeutic response.